Conventional dynamic contrast-enhanced MRI (DCE-MRI) has been used for tumor characterization based on tumor vascularity and permeability using non-targeted small molecular contrast agents. In this study, we investigate the effectiveness of DEC-MRI with a targeted MRI contrast agent for characterization of prostate cancer of different aggressiveness in comparison with a clinical agent. Distinctive Ktrans and Ve values were obtained between the high-risk PC3 and low-risk LNCaP tumors using the targeted agent, but not for the clinical agent, Gd(HP-DO3A). DCE-MRI with this targeted contrast agent could increase accuracy in characterizing prostate cancer aggressiveness.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords